References
- Limaye K. Psoriasis: an overview and update. Nurse Pract. 2015;40:23–6.
- Irimie M, Oanţă A, Irimie C, et al. Cardiovascular risk factors in patients with chronic plaque psoriasis: a case-control study on the brasov county population. Acta Dermatovenerol Croat. 2015;23:28–35.
- Ahlehoff O, Gislason GH, Lindhardsen J, et al. Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study. PLoS One. 2011;6:e18125
- Boehncke WH, Boehncke S. Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr Rheumatol Rep. 2012;14:343–8.
- Spah F. Inflammation in atherosclerosis andc psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol. 2008;159(suppl 2):10–7.
- Hjuler KF, Bøttcher M, Vestergaard C, et al. Association between changes in coronary artery disease progression and treatment with biologic agents for severe psoriasis. JAMA Dermatol. 2016;152:1114–21.
- Yim KM, Armstrong AW. Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms. Rheumatol Int. 2017;37:97–105.
- Raposo I, Torres T. Psoriasis strikes back! Epicardial adipose tissue: another contributor to the higher cardiovascular risk in psoriasis. Rev Port Cardiol. 2015;34:613–6.
- Fanf N, Jiang M, Fan Y. Association between psoriasis and subclinical atherosclerosis: a meta-analysis. Medicine (Baltimore). 2016;95:e3576.
- Rathcke CN, Vestergaard H. YKL-40-an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol. 2009;8:61
- Kastrup J. Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology. 2012;217:483–91.
- Harutyunyan M. The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure. Immunobiology. 2012;217:652–6.
- Persson F, Rathcke CN, Gall MA, et al. High YKL-40 levels predict mortality in patients with type 2 diabetes. Diabetes Res Clin Pract. 2012;96:84–9.
- Imai Y, Tsuda T, Aochi S, et al. YKL-40 (chitinase 3-like-1) as a biomarker for psoriasis vulgaris and pustular psoriasis. J Dermatol Sci. 2011;64:75–7.
- Alpsoy S, Akyuz A, Erfan G, et al. Atherosclerosis, some serum inflammatory markers in psoriasis. G Ital Dermatol Venereol. 2014;149:167–75.
- Imai Y, Aochi S, Iwatsuki K, et al. YKL-40 is a serum biomarker reflecting the severity of cutaneous lesions in psoriatic arthritis. J Dermatol. 2013;40:294–6.
- Ahmed SF, Attia EA, Saad AA, et al. Serum YKL-40 in psoriasis with and without arthritis; correlation with disease activity and high-resolution power Doppler ultrasonographic joint findings. J Eur Acad Dermatol Venereol. 2015;29:682–8.
- Erfan G, Guzel S, Alpsoy S, et al. Serum YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis? Mol Cell Biochem. 2015;400:207–12.
- Jensen P, Wiell C, Milting K, et al. Plasma YKL-40: a potential biomarker for psoriatic arthritis? J Eur Acad Dermatol Venereol. 2013;27:815–9.
- Ataseven A, Kesli R. Novel inflammatory markers in psoriasis vulgaris: vaspin, vascular adhesion protein-1 (VAP-1), and YKL-40. G Ital Dermatol Venereol. 2016;151:244–50.
- Johansen JS, Lottenburger T, Nielsen HJ, et al. Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol Biomarkers Prev. 2008;17:2603–8.
- Rathcke CN, Johansen JS, Vestergaard H. YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res. 2006;55:53–9.
- Hempen M, Kopp HP, Elhenicky M, et al. YKL-40 is elevated in morbidly obese patients and declines after weight loss. Obes Surg. 2009;19:1557–63.
- Nielsen AR, Erikstrup C, Johansen JS, et al. Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes. 2008;57:3078–82.
- Baran A, Flisiak I, Jaroszewicz J, et al. Effect of psoriasis activity on serum adiponectin and leptin levels. Postepy Dermatol Alergol. 2015;32:101–6.